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ABSTRACT 35 
Autocrine/paracrine factors generated in response to 17β-oestradiol (E2), within the 36 
oviduct, facilitate early embryo development for implantation. Since transforming 37 
growth factor beta1 (TGFB1) plays a key role in embryo-implantation, regulation of its 38 
synthesis by E2 may be of biological/pathophysiological relevance. Here we 39 
investigated whether oviduct cells synthesize TGFB1 and whether E2 and 40 
environmental-oestrogens (EOE’s; xenoestrogens and phytoestrogens) modulate its 41 
synthesis. Under basal conditions, bovine oviduct cells (OC’s; oviduct-epithelial cells 42 
and oviduct-fibroblasts; 1:1 ratio) synthesized TGFB1. E2 concentration-dependently 43 
induced TGFB1 levels in OC’s and these effects were mimicked by some, but not all 44 
EOE’s (genistein, biochanin-A and 4-hydroxy-2‘,4‘,6‘-trichlorobiphenyl, 4-hydroxy-45 
2‘,4‘,6‘-dichlorobiphenyl), moreover, EOE’s enhanced (P<.05) the stimulatory effects 46 
of E2 on TGFB1 synthesis. The OC’s expressed oestrogen receptors alpha and beta 47 
and aryl-hydrocarbon, moreover co-treatment with ER antagonist ICI182780 blocked 48 
the stimulatory effects of E2 and EOE’s on TGFB1 synthesis. Treatment with non-49 
permeable E2-BSA failed to induce TGFB1, thereby ruling out the involvement of 50 
membrane ER’s. Cycloheximide (protein-synthesis inhibitor) blocked E2-induced 51 
TGFB1 synthesis providing evidence for de novo synthesis. The stimulatory effects of 52 
E2 and EOE’s, were inhibited (P<.05) by MAPK-inhibitor (PD98059), whereas, 53 
intracellular-Ca2+ chelator (BAPTA-AM) and adenylyl cyclase-inhibitor (SQ22536) 54 
abrogated the effects of E2, but not EOE’s, suggesting that post-ER effects of E2 and 55 
EOE’s involve different pathways. Our results provide the first evidence that in OC’s, 56 
E2 and EOE’s stimulate TGFB1 synthesis via an ER-dependent pathway. Exposure 57 
of the oviduct to EOE’s may result in continuous/sustained induction of TGFB1 levels 58 
in a non-cyclic fashion and may induce deleterious effects on reproduction.  59 
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INTRODUCTION 60 
 61 
The oviduct plays a critical role in reproduction by providing an optimal 62 
microenvironment conducive for fertilization and initial stages of embryo development 63 
(Li and Winuthayanon 2017). Both rhythmic contraction and relaxation of oviduct 64 
smooth muscle cells and ciliary beats of oviduct epithelial cells are critically involved in 65 
transporting embryos and gametes (Li and Winuthayanon 2017). Multiple autocrine-66 
paracrine factors generated within the oviduct regulate its function (Li and 67 
Winuthayanon 2017). For example, oviduct cells produce nitric oxide (Rosselli et 68 
al.1998), hydrogen sulphide (Ning et al. 2014), prostaglandins (Abdel-Razek et al. 69 
2016), thromboxane (Huang et al. 2004), cyclic AMP (Cometti et al. 2003), leukaemia 70 
inhibitory factor (LIF1; Krishnan et al. 2013, Reinhart et al.1999), inflammatory 71 
cytokines, microRNA’s (Ibrahim et al 2015) and endothelin (Jeoung et al. 2010, 72 
Reinhart et al. 2003). 73 
 74 
TGFB, a 25-kDa homodimer peptide growth factor plays an important role in 75 
regulating growth, differentiation and metabolism in many mammalian cell types. It 76 
plays an important role in both adult and embryonic growth and development, 77 
inflammation and repair, including angiogenesis and regulation of host resistance 78 
mechanisms (Jones et al 2006, Li 2014, Monsivais et al. 2017). TGFB induces both 79 
autocrine and paracrine effects (Monsivais et al. 2017) and plays an important role in 80 
reproduction / the reproductive system (Jones et al. 2006, Li 2014, Monsivais et al. 81 
2017). TGFB has been detected in the human fallopian tube as well as in the human 82 
placenta, the human endometrial and embryonic tissues (Jones et al. 2006, Li 2014, 83 
Monsivais et al. 2017, Zhao et al. 1994). In human follicles, both theca and granulosa 84 
cells produce TGFB1 and TGFB2 (Monsivais et al. 2017), suggesting that it may be 85 
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involved in the regulation of follicular growth and oocyte maturation (Monsivais et al. 86 
2017). TGFB1 also regulates endometrial proliferation and differentiation and is 87 
involved in the paracrine regulation of trophoblast-endometrium interaction 88 
(Monsivais et al. 2017). Importantly, decreased-expression of TGFB1 in the uterus, 89 
during trophoblast invasion, results in failed embryo implantation (Monsivais et al. 90 
2017, Singh et al. 2011). Both TGFB1 and TGFB2 produced at the human foetal-91 
maternal interface plays a major regulatory role in the proliferation and differentiation 92 
of the trophoblast (Monsivais et al. 2017). Moreover, it regulates the local maternal 93 
immune response and prevents foetus rejection (Jones et al. 2006). Thus, TGFB is 94 
postulated to be necessary to maintain pregnancy. However, abnormal increases in 95 
TGFB are suggested to be a risk factor for recurrent miscarriages (Ogasawara et al. 96 
2000) and in ectopic pregnancy, linked to tubal disorders (Li et al.2011, Shaw et al. 97 
2010).  98 
 99 
Ovarian hormones like E2 regulate oviduct physiology. E2 influences oviduct 100 
function and the fertilization process by controlling the synthesis of 101 
autocrine/paracrine factors within the oviduct (Li and Winuthayanon 2017). In this 102 
context, we have previously shown that E2 induces the synthesis of LIF1 (Reinhart et 103 
al. 1999) which plays a key role in implantation. Moreover, we demonstrated that 104 
endothelin (ET1), a potent contracting and cell survival factor, is synthesized by 105 
bovine oviduct epithelial cells and induces the contraction of bovine oviduct 106 
segments (Jeoung et al. 2010, Reinhart et al. 2003).  107 
  108 
 Biological actions of E2 are largely mediated via nuclear oestrogen receptors 109 
(ER alpha and ER beta). However, non-genomic and non-nuclear 110 
receptors/mechanisms may also participate in mediating the pathophysiological 111 
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actions of E2 (Hewitt et al. 2016, Rosselli et al.2000). The endocrine effects of E2 112 
can be mimicked as well as blocked by chemicals that are structurally similar to E2, 113 
bind to ERs and possess estrogenic activity or modulate E2 metabolism by 114 
interacting with the aryl hydrocarbon receptor (AhR; Matthews & Gustafsson 2006, 115 
Rosselli et al. 2000, Shanle and Xu 2011). These oestrogen-like chemicals are 116 
termed EOE’s and are classified into two major categories: phytoestrogens (plant-117 
derived oestrogens) and xenoestrogens (man-made oestrogenic chemicals).  118 
 119 
Increasing evidence suggests that EOE’s act as endocrine disruptors and 120 
interfere with the reproductive process of humans and other species (Rosselli et al. 121 
2000, Shanle and Xu 2011). However, the mechanisms involved remain undefined. 122 
The fact that some EOE’s induce oestrogenic effects, whereas others act as anti-123 
oestrogenic (Rosselli et al. 2000, Shanle and Xu 2011), has further complicated the 124 
issue. Recent findings provide evidence that compared to E2, many EOE’s known to 125 
act as endocrine disruptors have a very low binding affinity for ER alpha and ER beta 126 
(Kuiper et al. 1998, Rosselli et al. 2000, Shanle and Xu 2011). This suggests that 127 
EOEs may mediate their effects via alternative ER-independent mechanisms such as 128 
modulating E2 metabolism (Matthews & Gustafsson 2006, Rosselli et al. 2000). 129 
 130 
Locally synthesized factors play a decisive role in regulating oviduct function 131 
by providing an optimal micro-environment for the transport of gametes, the 132 
fertilization process, and the development of an early embryo (Li and Winuthayanon 133 
2017). We previously demonstrated that oviduct cells produce/synthesize factors like 134 
LIF1 and ET1, and E2 simulates their synthesis. Moreover, EOE’s like 135 
phytoestrogens and polychlorinated biphenyls (PCBs) mimicked the effects of E2 on 136 
LIF1 (Reinhart et al. 1999), whereas contrasting effects were observed on ET1 137 
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(Reinhart et al 2003). Whether E2 regulates TGFB1 synthesis in the oviduct and 138 
whether EOE’s mimic the effects of E2 on TGFB1 synthesis remains unknown. 139 
 140 
Accordingly, the aims of the present study were to determine the following: (1) 141 
whether bovine oviduct cells synthesize TGFB1; (2) whether TGFB1 synthesis is 142 
regulated by E2; (3) whether the effects of E2 are mediated via de novo synthesis; 143 
(4) whether the effects of E2 and EOE’s on TGFB1 synthesis are ER operated; (5) 144 
whether EOE’s modulate the effects of E2 on TGFB1 synthesis; and (6) whether E2 145 
and EOE’s influence TGFB1 synthesis via similar intracellular mechanisms. 146 
 147 
MATERIAL AND METHODS 148 
Mixed Cultures: Oviducts of young, cyclic, non-pregnant cows were obtained 149 
from the local abattoir and the oviduct cells (OC’s; mixed population of epithelial cells 150 
and fibroblast, 1:1 ratio) were cultured in Ham’s F10 (Sigma, Chemie, Buchs 151 
Switzerland), containing 10% foetal calf serum (FCS, Sigma, steroid-free), according 152 
to our previously published method (Reinhart et al.1999). Briefly, we used confluent 153 
monolayers of OC’s cultured for 6–8 days. The mixed cell cultures of oviduct 154 
epithelial cells (OEC’s) and oviduct fibroblasts (OFCs) were characterized 155 
immunohistochemically as previously described (Reinhart et al. 1999). Monoclonal 156 
antibodies to epithelial cell cytokeratin, (anti-cytokeratin AE1/AE3; Dako Diagnostics 157 
AG, Zug, Switzerland.) and antibodies against fibroblast vimentin, (anti-vimentin VIM 158 
3B4; Dako) were used to identify OEC’s and OFC’s in culture. Stained cells were 159 
visualized using peroxidase, anti-peroxidase staining (Dako). TGFB1 antibodies 160 
(mouse monoclonal IgG; 25µg/ml; R&D systems) with anti-mouse horseradish 161 
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immunoperoxidase staining was used for immunostaining of TGFB1 in cultured OC’s. 162 
Staining of OC’s without primary antibodies was negative control.  163 
 164 
Cells in primary cultures or first passage were used to assess TGFB1 165 
synthesis. Prior to experiments with mixed cultures, preliminary studies in cultured 166 
oviduct fibroblasts (>97% purity) and epithelial cells (>90% purity) were conducted to 167 
assess TGFB1 production. Under basal conditions, oviduct epithelial cells (OECs), 168 
oviduct fibroblasts (OFCs) and OCs (OEC’s + OFC’s 1:1 ratio) produced TGFB1. In 169 
supernatants collected from cultured cells at 72 hours, the TGFB1 levels were 170 
611±95 pg/mg protein in OEC’s, 845±47 in OFC’s and 709±68 in mixed OC’s 171 
(Supplemental figure 1A). The production of TGFB1 in different oviduct cell 172 
preparations was comparable and treatment with E2 stimulated its synthesis by ≅ 173 
3.36±0.5 and 2.85±0.24 fold in OEC’s and OFC’s, respectively. In OC’s, the basal 174 
levels at 72 hours ranged between 696±14 to 785±70 pg/mg protein in different 175 
oviduct preparations and was induced by 3.2±0.35 fold in response to E2 (200ng/ml). 176 
Because autocrine/paracrine factors generated by both OEC’s and OFC’s may 177 
regulate the physiology and biology of the oviduct, we decided to use the mixed OC 178 
culture system to analyse the effects of natural and EOE’s on TGFB1 synthesis.  179 
 180 
Oviduct fibroblast cultures: Bovine OFC’s were isolated, characterized and 181 
cultured as previously described by us (Reinhart et al.1999). For all assays, we used 182 
cells in primary cultures or first passage. 183 
 184 
Treatment protocol for TGFB1 synthesis by OC’s: Sub-confluent 185 
monolayers of bovine OC’s were washed with HBSS and fed with Dulbecco’s 186 
Modified Eagle Medium (DMEM)/Ham’s F12 (Gibco), supplemented with 1% 187 
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charcoal-stripped FCS (Sigma, Buchs, Switzerland). After 3 days, we collected the 188 
culture medium and assayed immunoreactive TGFB1. To investigate whether TGFB1 189 
synthesis is time-dependent, we measured the TGFB1 level in conditioned media, 190 
collected at 24, 48 and 72 hours from OC cultures. To assess the regulation of 191 
TGFB1 synthesis by E2 and EOE’s, OC’s were treated for 72 hours in DMEM/Ham 192 
F12 medium (Sigma), supplemented with 1% steroid-free FCS and containing or 193 
lacking E2 (0.2, 2, 20, 100, 200 ng/ml; Sigma); genistein (200 ng/ml; Extrasynthèse, 194 
France); biochanin A (200 ng/ml; Extrasynthèse, France); 4: 2,4,6-trichlorobyphenyl 195 
(TCB, 200 ng/ml, AccuStandard); 4-hydroxy-2’,5’-dichlorobiphenyl (4-OH-DCB, 200 196 
ng/ml, AccuStandard); or 4-hydroxy-2’,4’,6’-trichlorobiphenyl (4-OH-TCB, 200 ng/ml, 197 
AccuStandard). To study whether basal and E2 stimulated increase in TGFB1 is due 198 
to de novo synthesis, OC’s were treated for 72 hours with E2 (200 ng/ml) in the 199 
presence or absence of cycloheximide (10µM, a protein synthesis inhibitor). To test 200 
whether the effects of E2 and EOE’s are mediated via ERs, OC’s were treated with 201 
E2, genistein, biochanin A, TCB, 4-OH-DCB and 4-OH-TDB (200 ng/ml) in the 202 
presence of 1uM - 10uM ICI182720 (ER-antagonist; Tocris, Bristol, UK). The 203 
rationale for using 1 and 10uM of ICI was based on the findings that the relative 204 
binding affinity of E2 and ICI182780 for ERs are 1 and 0.89, respectively. Moreover, 205 
the inhibitory potency (IC50) is 0.29 nM. Since, EOE’s have very low affinity for ERs 206 
as compared to E2 (Kuiper et al. 1998) , together with the fact that 10 fold higher 207 
concentrations of ICI have been shown to completely block the ER activating effects 208 
of E2, we elected to use a concentration of 1 and 10 uM for the experiments. 209 
Moreover, to analyse the possible role of the membrane ERs, OC’s were treated with 210 
the same concentration of E2 tagged to BSA, which is membrane impermeable (200 211 
ng/ml of E2 is equivalent to 1180ng/ml E2-BSA, Sigma). Finally, to assess 212 
involvement of intracellular mechanisms in mediating the effects of E2 and EOE’s on 213 
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TGFB1 synthesis, we used BAPTA-AM (a membrane permeable calcium chelator, 214 
1µM, Sigma), SQ22536 (adenylyl cyclase inhibitor, 500 µM, Sigma) and PD98059 215 
(MAPK inhibitor, 20 µM, Tocris Cookson LTD, Bristol, UK). For each experiment, the 216 
conditioned medium was collected to analyse TGFB1 levels, whereas, the remaining 217 
cells solubilized in 0.2% SDS and the protein levels were measured using BCA-218 
protein assay Kit (Soccochim SA, Lausanne, Switzerland). All experiments were in 219 
triplicate using three separate cultures derived from different pools of fresh oviducts. 220 
 221 
 TGFB1 ELISA: The presence of immune-reactive TGFB1 in conditioned 222 
medium (200µl aliquots) of OCs was analysed using an ELISA Kit (QuantikineTM, 223 
human TGFβ1 immunoassay; R&D Systems, Minneapolis, MN, USA). Briefly, 200 µl 224 
of activated samples (500 µl samples treated sequentially for 10 min with 100 µl 1N 225 
HCl, and 10 min with 100 µl 1.2N NaOH /0.5M Hepes) were added to a microplate 226 
coated with recombinant human TGFB sRII and incubated at RT for 3 hours. 227 
Subsequently, the plate was washed several times and 200 µl of polyclonal antibody 228 
against TGFB1 conjugated to horseradish peroxidase was added and further 229 
incubated at RT for 90 min. After washing the plate, 200 µl of substrate solution 230 
containing stabilized hydrogen peroxide and chromogen (tetramethylbenzidine) was 231 
added. After incubating at RT for 20 minutes, the reaction was terminated by adding 232 
50 µl of 2N sulfuric acid. The optical density was determined using a microplate 233 
reader, set to 450 nm, with a wavelength correction, set to 540 nm. According to the 234 
manufacturer’s specification, the minimal detectable concentration of TGFB1 was 235 
less than 7 pg/ml. TGFB1 concentrations were estimated using a standard curve run 236 
under identical conditions. TGFB1 concentrations were normalized against total cell 237 
protein and the results presented as percent of control. 238 
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Western Blotting:  Western blotting was used to further confirm the 239 
modulatory effects of E2 and EOE’s in OCs. Briefly, OCs treated were treated with 240 
E2, genistein, biochanin A and 4-OH-TCB (200 ng/ml) in the presence or absence of 241 
10uM ICI182720 (ER-antagonist). After 72 hours, the cells were lysed using 70ul of 242 
cell lysis buffer and combined with trichloroacetic acid (TCA; 10%) precipitated 243 
conditioned medium fraction of respective samples. Sample aliquots containing 25ug 244 
protein were electrophoretically resolved on a SDS gel under non reduced conditions 245 
and separated proteins transferred onto nitrocellulose. After blocking with 5% milk in 246 
PBS-Tween (Sigma), to prevent unspecific binding, the membranes were incubated 247 
with primary antibody for TGFB1 (TGFB1, mouse monoclonal; Santa Cruz 248 
Biotechnology, Inc.; dilution 4ug/ml). The membranes were washed and 249 
subsequently treated with the corresponding secondary antibody (goat anti-mouse 250 
IgG HRP peroxidase (1:5000 dilution). After washing the bands were determined 251 
using Super signal west dura luminol substrate (Pierce) and Hyperfilm ECL films 252 
(Amersham). Changes in TGFB1 were normalized to B-actin (Sigma; 1:5000 253 
dilution), using the LI-COR system. Briefly, membranes were incubated for 5 min with 254 
Newblot Nitro Stripping buffer and then washed 3x 10 min in PBS. Anti-B-actin 255 
mouse, Sigma (1:5000 dilution). IR Dye 800 conjugated Anti-mouse IgG LI-COR 256 
Biosciences 1:12500. Changes in protein expression were analysed by measuring 257 
optical density using Image J software and changes in protein expression presented 258 
as optical density ratio between TGFB1 and B-actin.  259 
 260 
To assess whether E2 and EOE’s activate MAPK pathway, OCs grown for 24 261 
hours in medium devoid of serum were treated for 15 minutes with E2, genistein, 262 
biochanin A and 4-OH-TCB (200 ng/ml) in the presence or absence of 10uM 263 
ICI182720 (ER-antagonist). The cells were lysed, resolved electrophoretically, and 264 
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probed for phosphorylated and non-phosphorylated MAPK using phosphospecific 265 
anti-MAPK mouse monoclonal antibody (phosphor-p44/42 MAPK; Thr202/Tyr204; 266 
Cell Signaling) and anti-p44/42 MAPK (ERK1/2) antibody (source rabbit; dilution 267 
1:1000; Cell Signaling).Corresponding HRP linked secondary antibody was used for 268 
detection. Changes in protein expression were analysed by measuring optical density 269 
using Image J software. Changes in protein expression presented as optical density 270 
ratio between phosphorylated MAPK (MAPK-P) and non-phosphorylated MAPK. 271 
 272 
Receptor Expression Studies: The expression of ERs and the aryl 273 
hydrocarbon receptor (AhR) in OCs was assessed using Western blotting. Briefly, 274 
OC lysates were probed with antibodies to ER alpha, ER beta or AhR, respectively. 275 
Antibodies for ER alpha (purified antiserum to human ER alpha), ER beta (purified 276 
antiserum to human ER beta), and AhR (rabbit polyclonal IgG against human AhR 277 
protein which recognized AhR at 96 and 122 kDa) were from Alexis, and diluted 278 
1:1000 in buffer containing 1% milk, PBS, 0.2% Tween-20. The secondary 279 
biotinylated antibodies (ImmunoPure goat Anti-Rabbit IgG, peroxidase conjugated, 280 
Pierce, Illinois, USA) diluted to 1:25000 in 1% milk, PBS, Tween 20 0.2% buffer, 281 
during 1h at RT. 282 
 283 
Statistical Analysis: Data are presented as a mean ± SEM of experiments 284 
conducted in triplicates (n=3). Statistical analysis was performed using ANOVA or 285 
Fischer’s least significant test, as appropriate. A value of P <0.05 was considered 286 
statistically significant. 287 
 288 
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RESULTS 289 
Effects of E2 on TGFB1 synthesis: We first established the optimal 290 
conditions for TGFB1 synthesis by the OCs (OECs plus OFCs; 1:1 ratio). They were 291 
used for all experiments unless specified otherwise. Figure 1A depicts OFCs 292 
positively stained with vimentin (brown staining marked a; negatively stained 293 
epithelial cells labelled b) in a representative OC culture. Western blotting of lysates 294 
(Figure 1B) collected from these cultures provides evidence for the presence of ERs 295 
alpha and beta, as well as the aryl hydrocarbon receptor (AhR; Figure 1B right 296 
panel; See Supplementary Figure 1B for original un-cut blot). Top panel of 297 
figure 1C shows the oviduct fibroblasts (middle panel) and epithelial cells (right 298 
panel) positively stained for TGFB1. The left panel depicts the negative control 299 
(neg-C). In cultured OCs, the level of TGFB1 increased in a time-dependent fashion 300 
and was 581.8±13.3, 720.4±14.3, and 785.7±70.7 pg/mg protein after 24, 48 and 72 301 
hours (p< 0.05 vs 0 hour), respectively (Figure 1C). Under similar culture conditions, 302 
we also observed production of immunoreactive TGFB1 in pure OECs and OFCs 303 
(Supplementary Figure 1A). To mimic the physiologic conditions within the oviduct, 304 
we used OCs to study the influence of test agents on TGFB1 production. 305 
 306 
Treatment of OCs with E2 (0.2, 2, 20, 100, 200 ng/ml) for 3 days increased 307 
TGFB1 levels in a concentration-dependent manner (Figure 2A). The lowest 308 
concentration of E2 that significantly increased TGFB1 levels was 100 ng/ml. At this 309 
concentration, E2 increased TGFB1 levels from 100% to 213 ± 15 % (p<0.05 310 
compared to vehicle treated control; Figure 2A). To assess whether increases in 311 
TGFB1 levels was solely due to de novo synthesis and not due to a release of stored 312 
intracellular proteins, OCs were treated with E2 in presence of cycloheximide, a 313 
selective protein synthesis inhibitor. Treatment of OCs with cycloheximide 314 
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significantly inhibited basal and E2 (200 ng/ml) stimulated synthesis of TGFB1 315 
(Figure 2B), suggesting that E2 induced TGFB1 production is due to de novo 316 
synthesis. 317 
 318 
The biological effects of E2 are mediated via ERs alpha and beta (Hewitt et al. 319 
2016; Levin et al. 2009), moreover its actions can be modulated by ligands (EOE’s or 320 
endocrine disruptors) for aryl hydrocarbon (AhR) receptors (Matthews & Gustafsson 321 
2006; Shanle and Xu 2011). Western blot analysis of cultured OC lysates provided 322 
evidence for the presence of both ERs alpha and beta as well as AhR (Figure 1B). 323 
To assess whether the stimulatory effects of E2 were ER mediated, we tested its 324 
effects in the presence and absence of ICI182780, an ER antagonist which binds 325 
with equal affinity to both ER alpha and beta (Kuiper et al. 1998). As shown in Figure 326 
3A, ICI182780 abrogated the stimulatory effects of E2 on TGFB1 production in a 327 
concentration-dependent manner, suggesting the actions are ER mediated.  328 
 329 
Recent studies provide evidence that E2 mediates its action via nuclear as 330 
well as membrane ER (Levin 2009). To assess whether E2 stimulates TGFB1 331 
synthesis via membrane ER, we treated OCs with membrane impermeable BSA 332 
tagged E2. As shown in Figure 3B, equimolar concentrations of E2 tagged to BSA 333 
failed to induce TGFB1 synthesis suggesting that E2 mediates its stimulatory actions 334 
via nuclear and not membrane-ER. 335 
 336 
Effects of Phytoestrogens on TGFB1 synthesis: Similar to E2, genistein (200 337 
ng/ml) significantly induced TGFB1 synthesis in OCs (p<0.05 vs control cells treated 338 
with vehicle). Treatment with genistein (200ng/ml) increased TGFB1 synthesis from 339 
100% in controls to 191%±19. Similar to genistein, TGFB1 synthesis was significantly 340 
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(p<0.05 vs untreated cells) increased in OCs treated with 200ng/ml biochanin-A, a 341 
precursor of genistein (Figure 4A). The stimulatory effects of both genistein and 342 
biochanin A on TGFB1 synthesis were completely blocked in the presence of ER 343 
antagonist ICI182780 (Figure 4A), suggesting that their effects were ER mediated. 344 
 345 
Effects of Xenoestrogens/PCBs: To evaluate the effects of PCBs on TGFB1 346 
synthesis, we treated OCs with 200 ng/ml of TCB, 4-OH-TCB and 4-OH-DCB. 347 
Treatment with 4-OH-TCB, but not TCB and 4-OH-DCB, induced TGFB1 production. 348 
The PCB 4-OH-TCB was as potent as E2 and increased TGFB1 production from 349 
100% in control to 275%±25.5 at a concentration of 200 ng/ml (Figure 4B). 350 
Moreover, the effects of 4-OH-TCB (200 ng/ml) on TGFB1 synthesis were blocked by 351 
ICI182780 (Figure 4B), suggesting they are ER mediated. 352 
 353 
Modulation of TGFB1 synthesis by E2 and EOE confirmed by Western 354 
Blotting: Although the ELISA assay is well established to accurately assess TGFB1 355 
levels, western blotting was also performed to rule out non-specific interference. 356 
Consistent with our observations with ELISA, treatment of OCs with 200ng/ml E2, 4-357 
OH-TCB, genistein or biochanin A induced TGFB1 expression and this stimulatory 358 
effect was abrogated in presence of 10µM ICI182780 (Figure 5).      359 
 360 
Modulatory effects of EOE plus E2: To investigate whether the effects of E2 361 
on TGFB1 synthesis were influenced in the presence of phytoestrogens and PCBs, 362 
we studied the effects of E2 (200 ng/ml) in the presence and absence of 200 ng/ml of 363 
genistein, biochanin A, TCB, 4-OH-DCB and 100 ng/ml 4-OH-TCB. As shown in 364 
figure 6A and 6B, EOE’s significantly increased the stimulatory effects of E2 on 365 
TGFB1 production. 366 
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 367 
Role of Ca++, PKA and MAPK on E2 and EOE induced TGFB1 synthesis: 368 
The mechanisms mediating the effects of E2 and EOEs on TGFB1 synthesis remains 369 
unclear. To study some of these possible pathways, cells in the first passage were 370 
treated with BAPTA-AM (membrane-permeable Ca2+ chelator, 1 µM), SQ22536 371 
(adenylyl cyclase inhibitor, 500 µM) and PD98059 (MAPK inhibitor, 20 µM). All the 372 
compounds showed a partial but significant (p<0.05) inhibition of E2 induced TGFB1 373 
synthesis (Figure 7). However, in contrast to E2, the stimulatory effects of 374 
phytoestrogens and PCBs were only inhibited by the MAPK inhibitor PD98059, 375 
suggesting that their effects are specifically mediated via the MAPK pathway and not 376 
via intracellular calcium release or the PKA pathway (Figure 8). 377 
 378 
Western blotting was performed to confirm the involvement of MAPK 379 
phosphorylation in mediating the stimulatory actions of E2 and EOE’s on 380 
TGFB1 production. As shown in Figure 9, treatment with 200ng/ml of E2, 4-OH-381 
TCB, genistein, or biochanin-A induced phosphorylated MAPK and this effect 382 
was blocked in OCs co-treated with 10uM ICI182780 (Figure 9). These findings 383 
provide evidence that E2 and EOE’s activate MAPK-P via ER dependent 384 
mechanism.   385 
 386 
To assess whether modulation of E2-induced TGFB1 production by various 387 
mechanisms (cyclic AMP, intracellular Ca2+, MAPK) are associated with or 388 
independent of ERs, OCs were treated with BAPTA-AM, SQ22.536 or PD98059 in 389 
the presence and absence of ICI182780. The attenuating effects of ICI182780 were 390 
not further enhanced by BAPTA-AM, SQ22536 and PD98050, suggesting that the 391 
stimulatory effects of E2 are mediated via a common pathway involving ER-392 
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dependent activation of intracellular calcium release, adenylyl cyclase and the MAPK 393 
pathway (Supplementary Figure 2A). 394 
 395 
Effects in OFC’s: Our results from cultured OFC’s (> 90%) were comparable to 396 
those obtained in OC’s. As shown in Figure 10, E2 (200 ng/ml), genistein (200 397 
ng/ml), biochanin A (200 ng/ml), as well as 4-OH-TCB (200 ng/ml), significantly 398 
induced (P<0.05) TGFB1 levels. These effects were partially (in cells treated with E2) 399 
or completely reversed (in cells treated with all other compounds) by the ER 400 
antagonist ICI182780 (1 and 10µM; Figure 10). We also observed similar effects in 401 
oviduct epithelial cells (Supplementary Figure 2B). 402 
 403 
 404 
DISCUSSION 405 
 406 
In the present study, we provide evidence that bovine OCs synthesize TGFB1 407 
under basal conditions. E2 stimulates TGFB1 production in OCs via ER and involves 408 
de novo protein synthesis. The stimulatory actions of E2 are mimicked by 409 
xenoestrogens (PCBs; TCBs, 4-OH-TCB and 4-OH-DCB) and phytoestrogens 410 
(genistein, biochanin-A). Moreover, EOE’s enhance the actions of E2 on TGFB1 411 
synthesis in additive fashion. E2 stimulates TGFB1 production in OC’s by regulating 412 
intracellular calcium, cyclic AMP and MAPK, whereas, EOE’s induced TGFB1 solely 413 
via MAPK, suggesting that the mechanisms via which natural and EOE’s induce 414 
TGFB1 are different. Our finding that EOE’s modulate local synthesis of TGFB1 415 
within the oviduct suggests that it may play an important role in regulating the biology 416 
and physiology of the oviduct associated with early embryo development. More 417 
importantly, in contrast to the cyclic effects of E2 on TGFB1 synthesis, continuous 418 
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exposure to EOE’s could induce TGFB1 levels in a non-cyclic fashion and may 419 
induce deleterious effects on the reproductive system. 420 
 421 
Cell-cell interaction between oviduct epithelial cells and oviduct fibroblasts 422 
plays an important role in maintaining the biological and physiological function of the 423 
oviduct by generating multiple autocrine/paracrine factors (Li and Winuthayanon 424 
2017, Singh et al. 2011). Hence, we employed OC’s, a mixed culture of OFCs and 425 
OECs (1:1 ratio), to assess TGFB1 synthesis in the oviduct. Our observation that 426 
TGFB1 levels increased in the conditioned medium of OCs in a time-dependent 427 
fashion suggests that the oviduct continuously synthesizes TGFB1 under basal 428 
conditions. 429 
 430 
Treatment with E2 stimulated TGFB1 production in OCs in a concentration-431 
dependent manner, moreover cycloheximide inhibited basal and E2 stimulated 432 
TGFB1 production in OCs. This suggests that basal and E2 stimulated TGFB1 433 
production is due to de novo synthesis and not simply a release of stored intracellular 434 
protein. Moreover, cyclic changes in the levels of E2 may regulate TGFB1 production 435 
and importantly, influence the biology and physiology of the oviduct in a timely 436 
fashion. TGFB1 plays an important role in embryo implantation, growth and 437 
differentiation (Li 2014, Li et al. 2011, Monsivais 2017). In this regard, cyclic changes 438 
in active TGFB1 expression occurs during the menstrual cycle (Arici et al. 2003). 439 
More importantly, increases in TGFB1 levels in the ovarian follicular fluid, following 440 
ovarian stimulation for vitro fertilization correlates with pregnancy (Fried et al. 1998). 441 
These observations indicate that E2, together with other cytokines, may stimulate the 442 
physiological release of TGFB1 within the oviduct and influence the priming and 443 
development of the early embryo for implantation. 444 
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 445 
Most biological effects of E2 are mediated via ERs alpha and/or beta (Hewitt 446 
et al. 2016). Our observation that pre-treatment with ICI182789, an ER antagonist 447 
with equal affinity for ER alpha and beta (Kuiper et al. 1998), abrogated the 448 
stimulatory effects of E2 on TGFB1, suggests that the effects of E2 are ER mediated. 449 
This contention is further supported by our finding that OCs expressed both ERs 450 
alpha and beta. Since biologically active ER has recently been identified in the 451 
membrane (Hewitt et al. 2016, Levin et al 2009), we also assessed its role in E2-452 
induced TGFB1 synthesis in OC’s. In contrast to E2, equimolar concentrations of E2 453 
tagged to BSA, which is membrane impermeable, failed to induce TGFB1 synthesis. 454 
This suggests that E2 stimulates TGFB1 production via nuclear, but not membrane 455 
ERs.  456 
 457 
Similar to E2, EOE’s bind to ERs and possess oestrogenic properties. These 458 
characteristics enable EOE’s to act as endocrine disrupters and potentially induce 459 
pathological affects within the reproductive system (Shanke and Xu 2011, Diamanti-460 
Kandarakis et al. 2009). Our findings provide the first evidence that EOE’s induce 461 
TGFB1 synthesis in bovine OC’s. Phytoestrogens, genistein and biochanin A, 462 
significantly induced TGFB1 synthesis in OC’s. As compared to genistein, biochanin 463 
A was less potent in inducing TGFB1 synthesis. Biochanin A is a precursor of 464 
genistein, with a 10,000-fold lower binding affinity than genistein for ERs (relative 465 
binding affinity of genistein for ER alpha and beta is 4 and 8, respectively, whereas 466 
binding for biochanin A is <0.01 for both ER alpha and ER beta; Kuiper et al. 1998). 467 
This indicates that the potency of EOE’s to induce TGFB1 depends on their binding 468 
affinity to ERs. This notion is supported by our observation that the stimulatory 469 
effects of both genistein and biochanin A were completely blocked by the ER 470 
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antagonist ICI182780. The fact that genistein and biochanin A are established 471 
agonists for ER beta suggests its involvement in mediating the stimulatory effects on 472 
TGF-B synthesis (Kuiper et al. 1998). E2 binds to both ER alpha and beta and is 473 
more potent than genistein and biochanin-A in stimulating TGFB1 synthesis. This 474 
suggests that ER alpha may play a role in stimulating TGFB1 synthesis. Experiments 475 
using specific ER alpha and beta agonists and antagonists are required to confirm 476 
this contention. 477 
 478 
Similar to E2 and phytoestrogens, PCB 4-OH-TCB, but not by TCB and 4-OH-479 
DCB, also induced TGFB1 production. As with phytoestrogens, differences in 480 
potency between the PCBs may largely be due to the differences in their binding 481 
affinity towards ERs. In fact, 4-OH-TCB is the molecule with the highest affinity 482 
(Kuiper et al. 1998). Moreover, the affinity for ER increases in ortho-chlorine 483 
substituted molecules and further enhanced in the hydroxylated ones. Thus, 4-OH-484 
DCB has a low affinity for ER (Shanle and Xu 2011) and the non-phenolic but ortho-485 
substituted TCB has very low or no affinity to ER (Shanle and Xu 2011). Our 486 
observation that ICI182780 blocked the stimulatory effects of 4-OH-TCB on TGFB1 487 
production suggests that the PCB effects are ER mediated. Since EOE’s can act as 488 
partial agonists or antagonists via nuclear or membrane ERs/GPER, this may, in 489 
part, contribute to the differences in action of natural and EOE’s. 490 
 491 
To confirm the stimulatory effects of E2 and EOE’s on TGFB1 synthesis by 492 
OCs were real and not due to non-specific cross reactivity with some other proteins, 493 
we confirmed their actions using western blotting. Consistent with the results from 494 
ELISA assay, we observed upregulation of TGFB1 protein expression (≈26kDa 495 
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protein) by E2 and EOE’s. Moreover these effects were blocked by ICI182780 496 
(10uM), reaffirming the notion that the effects are ER mediated.   497 
 498 
The above findings suggest that EOE’s may induce their deleterious effects in 499 
the reproductive system by modulating TGFB1. Indeed, TGFB1 plays an important 500 
role in embryo growth and development as well as in the regulation of the local 501 
maternal immune response to prevent miscarriage (Li 2014, Singh et al 2011). 502 
Importantly, TGFB1 is critical in wound healing and fibrotic scar tissue formation and 503 
implicated in tubal abnormalities associated with ectopic pregnancy (Shaw et al. 504 
2010). Hence, we assessed and compared the effects of E2 and the EOE’s on 505 
TGFB1 synthesis by OFC’s. Similar to the effects in OC’s, we found that EOE’s 506 
mimic the stimulatory effects of E2 on TGFB1 synthesis in OFC’s. Our findings 507 
suggest that EOE’s can potentially trigger non-cyclic TGFB1 production locally and 508 
contribute to pathological remodelling of fallopian tube associated with adhesions. 509 
 510 
Our finding that the phytoestrogens and PCBs enhance the stimulatory effects 511 
of E2 on TGFB1 production suggests that exposure to EOE’s can result in non-512 
physiological increase of TGFB1 in the oviduct and induce deleterious actions on the 513 
reproductive process. Interestingly, 4OH-DCB, which was ineffective in inducing 514 
TGFB1 alone, enhanced the effects of E2, suggesting that EOE’s with weak 515 
oestrogenic activity can also modulate oestrogenic responses in the presence of 516 
other endogenous oestrogens. Since cyclic generation of E2 allows events and 517 
regulatory feedback to take place at the right moment (Kiyama and Wada-kiyama 518 
2015), presence of EOE’s may disrupt this balance. Moreover, in contrast to E2, 519 
EOE’s may accumulate in fatty tissues and be present in the body for a long time, 520 
resulting in constant ER activation and adverse health effects (Shanle and Xu 2011). 521 
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 522 
Whether non-cyclic, abnormally high levels of TGFB1 may play a role in tubal 523 
infertility can only be speculated. Increased incidences of ectopic pregnancies have 524 
been observed after recurrent surgery for pelvic adhesions, presence of adenomas, 525 
fibrotic scar tissues following wound healing, ovarian hyper-stimulation, and local 526 
infections, moreover, these conditions are also associated with an increase in TGFB1 527 
levels (Li et al 2014, Shaw et al. 2010, Tonello & Polli 2007, Xiong et al 2013). For 528 
example, Li et al (2011) reported high expression of TGFB1 in occluded fallopian 529 
tubes. Since TGFB1 is a master regulator of fibrosis (Meng et al. 2016), it is feasible 530 
that increased or abnormal exposure to EOE’s may induce TGFB1 levels which could 531 
adversely influence oviduct function and biology leading to tubal occlusion and 532 
dysfunction. Indeed, exposure to exogenous oestrogens like DES has been 533 
associated with unfavourable pregnancy outcomes, including ectopic pregnancy 534 
(Palmer et al 2001). Although, multiple factors may contribute to tubal disorders, the 535 
autocrine/paracrine role of TGFB1 in response to oestrogens and ER activation may 536 
be critical in early embryo priming and transport. It is feasible that continuous 537 
presence of abnormally high TGFB1 levels, in response to high E2 or EOE’s 538 
exposure, triggers implantation like conditions within the oviduct leading to ectopic 539 
pregnancies. 540 
 541 
E2 activates intracellular calcium, adenylyl cyclase and MAPK via non-542 
genomic mechanisms (Nilsson et al 2001). Since these pathways actively induce 543 
TGFB1 formation, they may in part mediate the stimulatory effects of E2 on TGFB1. 544 
Indeed, similar to ICI182780, intracellular calcium chelator BAPTA-AM, adenylyl 545 
cyclase inhibitor SQ22536 and the MAPK inhibitor PD98059, abrogated the 546 
stimulatory effects of E2. Since the inhibitory effects of BAPTA-AM, SQ22536 and 547 
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PD98059 were not additive, nor did they modulate the effects of ICI182780, suggests 548 
that they inhibit via a common mechanism linked to ER. This contention is supported 549 
by our finding that ICI12780 blocked the stimulatory effects of E2 and EOEs on 550 
MAPK phosphorylation. Interestingly, MAPK inhibitor PD98059, but not Ca2+ and 551 
adenylyl cyclase inhibitors, abrogated the stimulatory effects of EOE’s 552 
(phytoestrogen and PCBs) on TGFB1, suggesting that E2 and EOE’s mediate their 553 
stimulatory actions on TGFB1 via MAPK activation. 554 
 555 
  The ER antagonist blocked the effects of phytoestrogens and PCBs 556 
suggesting that they are ER mediated. However, we cannot rule out the participation 557 
of other mechanisms. Both phytoestrogens and PCBs are AhR ligands and cross talk 558 
between ERs and AhRs influence ER expressions and transcriptional activation. 559 
Silencing of AhR lowers/inhibits TGFB1 production (Gramatzki et al. 2009) and the 560 
OCs express AhR. Interestingly, PD98056, which blocked the stimulatory effects of 561 
EOE’s, is also an AhR antagonist (Reiners et al. 1998) and may have blocked the 562 
effects of EOE’s on TGFB1 via this mechanism. Further in-depth studies are required 563 
to test these possibilities. 564 
 565 
Almost every cell in the body produces some form of TGFB and express 566 
TGFB receptors, suggesting an important role in preventing disease. Within the 567 
female reproductive system, TGFB1 is involved in embryo implantation, growth and 568 
differentiation, placental differentiation, endometrium proliferation and differentiation, 569 
trophoblast-endometrium interaction during trophoblast invasion into the uterus, 570 
cytokine network regulation during pregnancy to maintain a healthy foetus, immune-571 
suppressor to regulate the maternal immune response and avoid miscarriage (Jones 572 
et al. 2006, Li 2014). TGFB levels peak during the window of implantation, which 573 
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prepares the uterine for embryo implantation by modulating immune responses and 574 
localized/controlled apoptosis of endometrial stromal cells and tissue remodelling (Li 575 
and Winuthayanon 2017). TGFB regulates angiogenesis and its expression at the 576 
embryo–uterine interphase, thought to play a critical role in placenta development (Li 577 
2014; Li and Winuthayanon 2017). Although an increase in TGFB1 in follicular fluid 578 
following ovarian stimulation and in-vitro fertilization correlates with pregnancy (Fried 579 
& Wramsby 1998), abnormally high TGFB1 levels are associated with miscarriages 580 
(Ogasawara et al. 2000). 581 
 582 
In conclusion, our findings provide evidence that E2 and EOE’s regulate 583 
TGFB1 synthesis in oviduct cells. EOE mediated non-physiologic stimulation of 584 
TGFB1 synthesis within the oviduct may play an important role in governing the role 585 
of the oviduct in the biology and pathophysiology of reproduction. 586 
 587 
Declaration of Interest: There is no conflict of interest, which could be perceived as 588 
prejudicing the impartiality of the research reported. 589 
 590 
Funding: Supported by the Swiss National Sciences Foundation grant 32-55738.98 591 
and 31003A-138067. 592 
 593 
Acknowledgements: The data presented in this manuscript was, in part, the PhD 594 
dissertation (Diss., Naturwissenschaften ETH Zürich, Nr. 14994, 2003) work 595 
submitted by Barbara Cometti to ETH Zurich, Switzerland.   596 
http://dx.doi.org/10.3929/ethz-a-004540868. 597 
598 
Page 23 of 44
 24 
 
REFERENCES 599 
Arici A, Sozen I 2003 Expression, menstrual cycle-dependent activation, and 600 
bimodal mitogenic effect of transforming growth factor-B1 in human myometrium and 601 
leiomyoma. Am J Ostet Gynecol 188 76-83. 602 
Cometti B, Dubey RK, Imthurn B, Jackson EK, Rosselli M 2003 Oviduct cells 603 
express the cyclic AMP-adenosine pathway. Biol Reprod 69 868-875. 604 
Diamanti-Kandarakis E, Bourguignon J-P, Giudice LC, Hauser R, Prins GS, 605 
Soto AM, Zoeller RT, Gore AC 2009 Endocrine-disrupting chemicals :An endocrine 606 
society scientific statement. Endocrine Rev 30 293-342. 607 
Fried G, Wramsby H 1998 Increase in transforming growth factor beta1 in ovarian 608 
follicular fluid following ovarian stimulation and in-vitro fertilization correlates to 609 
pregnancy. Hum Reprod 13 656-659. 610 
Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, 611 
Schwarz M, Weller M, Tritschler I 2009 Aryl hydrocarbon receptor inhibition 612 
downregulates the TGF-B/Smad pathway in human glioblastoma cells. Oncogene 28 613 
2593-2605. 614 
Hewitt SC, Winuthayanon W, Korach KS 2016 What’s new in estrogen receptor 615 
action in the female reproductive tract. J Mol Endocrinol 56 R55-R71. 616 
Huang J-C, Goldsby JS, Arbab F, Melhem Z, Aleksic N, Wu KK 2004 Oviduct 617 
prostacyclin functions as a paracrine factor to augment the development of embryos. 618 
Human Reproduction 19 2907-2912. 619 
Ibrahim S, Salilew-Wondim D, Rings F, Hoelker M, Neuhoff C, Tholen E, Looft C, 620 
Schellander K, Tesfaye D 2015 Expression pattern of inflammatory response genes 621 
and their regulatory microRNAs in bovine oviductal cells in response to 622 
liposaccharide: Implication for early embryonic development. PLOS ONE 10(3) 623 
e0119388. DOI:10.1371/journal.pone.01 19388 624 
Page 24 of 44
 25 
 
Jeoung M, Lee S, Hawng H-k, Cheon Y-P, Jeong YK, Gye MC, Iglarz M, Ko C, 625 
Bridges PJ 2010 Identification of a novel role of endothelins within the oviduct. 626 
Endocrinology 151, 2858-2867. 627 
Jones RL, Stoikos C, Findlay JK, Salamonsen LA 2006 TGF-β superfamily 628 
expression and actions in the endometrium and placenta. Reproduction 132 217-232. 629 
Kiyama R, Wada-Kiyama Y 2015 Estrogenic endocrine disruptors: molecular 630 
mechanism of action. Environmental International 83 11-40. 631 
Krishnan T, Winship A, Sonderegger S, Menkhorst E, Horne AW, Brown J, 632 
Zhang J-G, Nicola NA, Tong S, Dimitriadis E 2013 The role of leukemia inhibitory 633 
factor in tubal ectopic pregnancy. Placenta 34 1014-1019. 634 
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van 635 
der Burg B, Gustafsson JA 1998 Interaction of estrogenic chemicals and 636 
phytoestrogens with estrogen receptor beta. Endocrinology 139 4252-4263. 637 
Levin ER 2009 Plasma membrane estrogen receptors Trends Endocrinol Metab 20 638 
477-482. 639 
Li Q 2014 Transforming growth factor β signaling in uterine development and 640 
function. J Animal Science and Biotech 552 (doi.10.1186/2049-1891-5-52). 641 
Li Z, Sun Y, Min W, Zhang D 2011 Correlation between overexpression of 642 
transforming growth factor-beta 1 in occluded fallopian tubes and postsurgical 643 
pregnancy among infertile women. Int J Gynecol and Obstetrics 112 11-14. 644 
Li S, Winuthayanon W 2017 Oviduct: roles in fertilization and early embryo 645 
development. J Endocrinol 232 R1-R26 646 
Matthews J, Gustafsson J-A 2006 Estrogen receptor and aryl hydrocarbon receptor 647 
signaling pathways. Nuclear Receptor Signaling 4 e016. 648 
Meng X-m, Nikolic-Paterson DJ, Lan HY 2016 TGF-B, the master regulator of 649 
fibrosis. Nature Reviews Nephrology 12 325-338. 650 
Page 25 of 44
 26 
 
Monsivais D, Matzuk MM, Pangas SA. 2017 The TGF-β family in the reproductive 651 
tract. Cold Spring Harb Perspect Biol doi:10.1101/cshperspect.a022251. 652 
Nilsson S, Mäkela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark 653 
E, Pettersson K, Warner M, Gustafsson J-A 2001 Mechanism of Estrogen Action. 654 
Physiol Rev 81 1535-1565. 655 
Ning N, Zhu J, Du Y, Gao X, Liu C, Li J 2014 Dysregulation of hydrogen sulphide 656 
metabolism impairs oviductal transport of embryos. Nature Communications 5 4107 657 
(doi:10.1038/ncomms5107). 658 
Ogasawara MS, Aoki K, Aoyama T, Katano K, Iinuma Y, Ozaki Y, Suzumori K. 659 
2000 Elevation of transforming growth factor-beta1 is associated with recurrent 660 
miscarriage. J Clin Immunol 20 453-457. 661 
Palmer JR, Hatch EE, Rao RS, Kaufman RH, Herbst AL, Noller KL, Titus-662 
Ernstoff L, Hoover RN 2001 Infertility among women exposed prenatally to 663 
Diethylstilbestrol. Am J Epidemiol 154 316-312. 664 
Reiners JJ, Jr., Lee JY, Clift RE, Dudley DT, Myrand SP 1998 PD98059 is an 665 
equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-666 
activated protein kinase kinase. Mol Pharmacol 53 438-445. 667 
Reinhart KC Dubey RK, Keller PJ, Lauper U, Rosselli M 1999 Xenoestrogens and 668 
Phytoestrogens induce the synthesis of leukemia inhibitory factor by human and 669 
bovine oviduct cells. Mol Hum Reprod 5 899-907. 670 
Reinhart KC, Dubey RK, Cometti B, Keller PJ, Rosselli M 2003 Differential effects 671 
of natural and environmental estrogens on endothelin synthesis in bovine oviduct 672 
cells. Biol of Reprod 68 1430-1436. 673 
Rosselli M, Dubey RK, Rosselli MA, Macas E, Fink D, Lauper U, Keller PJ. 674 
Imthurn B 1998 Role of nitric oxide in the biology, physiology and pathophysiology of 675 
reproduction. Hum Reprod Update 4 3-24. 676 
Page 26 of 44
 27 
 
Rosselli M, Reinhart K, Imthurn B, Keller PJ, Dubey RK 2000 Cellular and 677 
biochemical mechanisms by which environmental estrogens influence reproductive 678 
function. Human Reprod Update 6 332-350. 679 
Shanle EK, Xu W 2011 Endocrine disrupting chemicals targeting estrogen receptor 680 
signaling: identification and mechanisms of action. Chem Res Toxicol 14 6-19.  681 
Shaw JLV, Dey SK, Critchley HOD, Horne AW 2010 Current knowledge of the 682 
aetiology of human tubal ectopic pregnancy. Human Reproduction Update 16 432-683 
444. 684 
Singh M, Chaudhry P, Asselin E 2011 Bridging endometrial receptivity and 685 
implantation: network of hormone, cytokines, and growth factors Journal of 686 
Endocrinology 210 5-14. 687 
Tonello A, Poli G 2007 Tubal ectopic pregnancy:macrophages under the 688 
microscope. Human Repord 22 2577-2584. 689 
Xiong W Frasch SC, Thomas SM, Bratton DL, Henson PM 2013 Induction of TGF-690 
B1 synthesis by macrophages in response to apoptotic cells requires activation of 691 
scavenger receptor CD36 PLOS one 8: e72772. 692 
Yousef MA, Marey MA, Hambruch N, Hayakawa H, Shimizu T, Hussien HA, 693 
Abdel-Razek A-R K, Pfarrer C, Miyamoto A 2016 Sperm binding to oviduct 694 
epithelial cells enhances TGFB1 and IL10 expressions in epithelial cells as well as 695 
neutrophils in vitro: prostaglandin E2 as a main regulator of anti-inflammatory 696 
response in the bovine oviduct. PLoS ONE 1(9):e0162309. 697 
Page 27 of 44
FIGURE LEGENDS 
 
Figure 1: Panel A: Depicts representative photomicrographs (40X mag) of bovine 
oviduct cells (mixed cultures of oviduct fibroblasts plus oviduct epithelial cells; 
primary cultures) with positive immunohistochemically labelling of oviduct fibroblasts 
with monoclonal antibodies against fibroblast vimentin (anti vimentin VIM 3B4) 
marked with an arrow (a) and negatively stained epithelial cells (b). Panel B: Left 
panel depicts representative Western Blots depicting the expression of ERs alpha 
and beta in lysates from bovine oviduct cells. Right Panel shows representative 
Western Blot for expression aryl hydrocarbon (AhR) receptors in lysates from bovine 
oviduct cells. Panel C: Top panel shows representative photomicrograph of oviduct 
fibroblasts (middle panel) and epithelial cells (right panel) with positive immuno-
staining for TGFB1 whereas the left panel depicts the negative control. Lower panel 
depicts bar graph time dependent synthesis of TGFB1 by confluent monolayers of 
bovine oviduct cells. TGFB1 levels were measured in conditioned medium collected 
at 0, 24, 48 and 72 hours of culture. The graph represents mean of three different 
experiments. Data (mean ± SEM) are expressed as pg/mg protein. (* p < 0.05 vs 0h). 
 
Figure 2: Panel A: Bar graph showing the concentration-dependent effects of 17B-
oestradiol (0.2-200 ng/ml) on the TGFB1 synthesis by cultured oviduct cells. Data 
(mean ± SEM) represent the mean of three different experiments (n=3, in triplicates). 
All values were normalized to total protein concentration and the amount of TGFB1 
synthesized is express as percent (%) of control. (*p<0.05 vs control; Cont). Panel B: 
Bar graph showing the modulatory effects of cyclohexamide (CHX; 10µM on 17B-
oestradiol (E2; 200 ng/ml) induced synthesis of TGFB1 by cultured bovine oviduct 
cells treated for 72 hours. Data (mean ± SEM) represents mean of three different 
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experiments (n=3, triplicates). The values were normalized to total protein 
concentration and expressed as pg/mg protein (§ represents significant inhibition, p < 
0.05 vs control or E2; * p<0.05 vs control).  
 
Figure 3: Panel A:  Bar graph showing the concentration-dependent inhibitory 
effects of ER-antagonist ICI182780 (ICI; 1 and 10µM) on 17β-oestradiol (E2; 
200ng/ml) induced TGFB1 synthesis in oviduct cells treated for 72 hrs. Data (mean ± 
SEM) represents the mean of three different experiments (n=3, in triplicates) and 
values were normalized to total protein concentration. The amount of TGFB1 
synthesized is expressed as percent (%) of control. (* p<0.05 vs control, Cont; § 
p<0.05 vs E2 alone or -ICI). Panel B: Bar graph comparing the effects of 200ng/ml of 
17β-oestradiol (E2) tagged with or without BSA (E2 or E2-BSA), on TGFB1 synthesis 
by cultured bovine oviduct cells. E2, but not E2-BSA, induced TGFB1 formation. Data 
(mean ± SEM) represent the mean of three different experiments (n=3, triplicates) 
and values were normalized to total protein concentration. The amount of TGFB1 
synthesized is expressed as percent (%) of control (Con; * p < 0.05 vs control). 
 
Figure 4: Bar graph showing the modulatory effects of ICI182780 (1 and10 µM), on: 
Panel A: 17B-oestradiol (E2, 200ng/ml), genistein (200ng/ml), biochanin A (200 
ng/ml), and panel B:  TCB (200ng/ml), 4-OH-TCB (200ng/ml) and 4-OH-DCB (200 
ng/ml) stimulated synthesis of TGFB1 by cultured oviduct cells, treated for 72 hours. 
Data (mean ± SEM) represents the mean of three different experiments (n=3, in 
triplicates) and values were normalized to total protein concentration. The amount of 
TGFB1 synthesized is expressed as percent (%) of control. (* p<0.05 vs control; § 
p<0.05 vs - ICI182780). 
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 Figure 5:  Top panel depicts a representative western blot showing the 
modulatory effects of effects 17B-oestradiol (E2, 200ng/ml), genistein 
(200ng/ml), biochanin A (Bio-A; 200 ng/ml), 4-OH-TCB (200ng/ml) on 
TGFB1synthesis by cultured oviduct cells, treated for 72 hours in presence and 
absence of 10uM ICI182780. Lower panel shows the changes in optical density 
from the contrast adjusted blot using image J program. The data depicts 
change in TGFB1/B-actin ratio from three separate experiments (* p<0.05 vs 
control; § p<0.05 vs - ICI182780).  
 
Figure 6: Panel A:  Bar graph showing the modulatory effects of 17β -oestradiol (E2; 
200 ng/ml), on Genistein (200 ng/ml), biochanin A (BioA; 200 ng/ml) and (Panel B) 
on E2 (200 ng/ml), TCB (200 ng/ml), 4-OH-TCB (100 ng/ml) and 4-OH-DCB (200 
ng/ml) stimulated synthesis of TGFB1 by cultured bovine oviduct cells treated for 72 
hours. Data (mean ± SEM) represent the mean of three different experiments (n=3, 
triplicates) and values were normalized to total protein concentration. The amount of 
TGFB1 synthesized is expressed as percent (%) of control. (*p<0.05 vs control). * 
p<0.05 versus control (Con), § p<0.05 versus respective treatment in absence of E2 
(-E2). 
 
Figure 7: Bar graph showing the modulatory effects of BAPTA-AM (1 µM), SQ22.536 
(500 µM) and PD98059 (20 µM) on 17β-oestradiol (E2; 200 ng/ml) stimulated 
synthesis of TGFB1 by cultured bovine oviduct cells treated for 72 hours. Data (mean 
± SEM) represent the mean of three different experiments (n=3, triplicates) and 
values were normalized to total protein concentration. The amount of TGFB1 
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synthesized is expressed as percent (%) of control. (*p<0.05 vs control (C), § p<0.05 
vs + E2). 
 
Figure 8: Bar graph showing the modulatory effects of BAPTA-AM (1 µM), SQ22536 
(500 µM) and PD98059 (20 µM) on environmental oestrogen’s induced TGFB1 
synthesis in cultured bovine oviduct cells. Cells were treated for 72 hours with 
genistein (200ng/ml) or 4OH-TCB (200ng/ml) in the presence or absence of BAPTA-
AM, SQ22536 or PD98059. Data (mean ± SEM) represent the mean of three different 
experiments (n=3, triplicates) and values were normalized to total protein 
concentration. The amount of TGFB1 synthesized is expressed as percent (%) of 
control. *p<0.05 versus genistein or 4OH-TCB, respectively, in controls, § p<0.05 
versus + Genistein or + 4OH-TCB, respectively, in control. 
 
Figure 9:  Top panel depicts a representative western blot, showing the modulatory 
effects of effects 17B-oestradiol (E2, 200ng/ml), genistein (200ng/ml), biochanin A 
(200 ng/ml), 4-OH-TCB (200ng/ml) on MAPK activation (MAPK-P) by cultured oviduct 
cells, stimulated in presence and absence of 10uM ICI182780. Lower panel shows 
the changes in optical density from contrast adjusted blot using Image J program. 
The graph depicts change in ratio between phosphorylated and non-phosphorylated 
MAPK-P/MAPK from three separate experiments.  (* p<0.05 vs control; § p<0.05 vs - 
ICI182780). 
 
Figure 10: Top Panel:  Bar graph showing the modulatory effects of ICI182780 (1µM 
and 10µM) on 17β-oestradiol (E2; 200 ng/ml), Genistein (200 ng/ml), biochanin A 
(Bio-A, 200 ng/ml) and (Bottom Panel) on TCB (200 ng/ml), 4-OH-TCB (100 ng/ml) 
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and 4-OH-DCB (200 ng/ml) stimulated synthesis of TGFB1 by cultured bovine 
oviduct fibroblasts. Data (mean ± SEM) represents the mean of three different 
experiments (n=3, triplicates) and values were normalized to total protein 
concentration. The amount of TGFB1 synthesized is expressed as percent (%) of 
control. *p<0.05 vs control; § p<0.05 versus – ICI in respective treatments. 
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Legends to Supplementary Figures: 
Supplementary Figure 1A: Bar graph showing TGFB1 by culured bovine oviduct 
epithelial cells (OECs), oviduct fibroblasts (OFCs) and oviduct mixed cells (OECs : 
OFCs 1:1 ratio). TGFB1 levels were measured in conditioned medium collected after 
72 hours in culture. The graph represents mean of three different experiments. Data 
(mean ± SEM) are expressed as pg/mg protein/72 hr. 
Supplementary Figure 1B: Representative uncut Western blots showing the 
expression of ER alpha, ER beta (left panel) and Aryl hydrocarbon receptor (right 
panel) in cultured OCs. The white arrows indicate the specific bands for the proteins. 
Supplementary Figure 2A: Bar graph showing the modulatory effects of BAPTA-AM 
(1 µM), SQ22.536 (500 µM) and PD98059 (20 µM) in presence of ER antagonist 
ICI182780 (0.5µM) on 17β-oestradiol (E2; 200 ng/ml) induced synthesis of TGFB1 by 
cultured bovine oviduct cells. Data (mean ± SEM) represent the mean of three 
different experiments (n=3, triplicates) and values were normalized to total protein 
concentration. The amount of TGFB1 synthesized is expressed as percent (%) of 
control. (*p<0.05 vs control (C), § p<0.05 vs E2 alone). 
Supplementary Figure 2B: Bar graph showing the modulatory effects of ICI182780 
(1µM and 10µM) on 17B-oestradiol (E2; 200 ng/ml), Genistein (200 ng/ml), biochanin 
A (Bio-A, 200 ng/ml) and on TCB (200 ng/ml), 4-OH-TCB (100 ng/ml) and 4-OH-DCB 
(200 ng/ml) stimulated synthesis of TGFB1 by cultured bovine oviduct epithelial cells. 
Data (mean ± SEM) represents the mean of three different experiments (n=3, 
triplicates) and values were normalized to total protein concentration. The amount of 
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TGFB1 synthesized is expressed as percent (%) of control. *p<0.05 vs control § 
p<0.05 versus –ICI in respective treatment.  
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Figure 4  
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Figure 5  
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Figure 6  
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Figure 7  
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Figure 8  
 
190x254mm (96 x 96 DPI)  
 
 
Page 42 of 44
  
 
 
Figure 9  
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